Answers are grounded in this paper and cite their sources.
Isocitrate Dehydrogenase 1/2 (IDH 1/2)-wildtype (WT) astrocytomas constitute a heterogeneous group of tumors and have undergone a series of diagnostic reclassifications over time. This study aimed to investigate molecular markers, clinical, imaging, and treatment factors predictive of outcomes in WHO grade 2/3 IDH-WT astrocytomas ('early glioblastoma').
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: